Schackman, Bruce R.

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 332

. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.

Losina, E., Schackman, B. R., Sadownik, S. N., Gebo, K. A., Walensky, R. P., Chiosi, J. J., Weinstein, M. C., Hicks, P. L., Aaronson, W. H., Moore, R. D., et al. (2009) · Clinical Infectious Diseases

HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Cited by 180

Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort

Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019) · Drug and Alcohol Dependence

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 159

Effect of Risk-Reduction Counseling With Rapid HIV Testing on Risk of Acquiring Sexually Transmitted Infections: The AWARE Randomized Clinical Trial

Metsch, L. R., Feaster, D. J., Gooden, L., Schackman, B. R., Matheson, T., Das, M., Golden, M. R., Huffaker, S., Haynes, L. F., Tross, S., et al. (2013) · JAMA

HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual Risk

Cited by 130

The lifetime medical cost savings from preventing HIV in the United States

Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., et al. (2015) · Medical Care

HIV/AIDS Research and InterventionsHealth Systems, Economic Evaluations, Quality of Life

Cited by 123

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 101

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012) · Journal of General Internal Medicine

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 100

Projected estimates of opioid mortality after community-level interventions.

Linas, B. P., Savinkina, A., Madushani, R. W. M. A., Wang, J., Eftekhari Yazdi, G., Chatterjee, A., Walley, A. Y., Morgan, J. R., Epstein, R. L., Assoumou, S. A., et al. (2021) · JAMA Network Open

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 72

Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Linas, B. P., Wong, A. Y., Schackman, B. R., Kim, A. Y., & Freedberg, K. A. (2012) · Clinical Infectious Diseases

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 61

Measuring benefits of opioid misuse treatment for economic evaluation: health‐related quality of life of opioid‐dependent individuals and their spouses as assessed by a sample of the US population

Wittenberg, E., Bray, J. W., Aden, B., Gebremariam, A., Nosyk, B., & Schackman, B. R. (2016) · Addiction

Opioid Use Disorder TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 45

Monetary conversion factors for economic evaluations of substance use disorders

McCollister, K., Yang, X., Sayed, B., French, M. T., Leff, J. A., & Schackman, B. R. (2017) · Journal of Substance Abuse Treatment

Health Systems, Economic Evaluations, Quality of LifeSubstance Abuse Treatment and Outcomes

Cited by 43

Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island

Zang, X., Bessey, S. E., Krieger, M. S., Hallowell, B. D., Koziol, J. A., Nolen, S., Behrends, C. N., Murphy, S. M., Walley, A. Y., Linas, B. P., et al. (2022) · JAMA Network Open

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 26

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

Flam-Ross, J. M., Marsh, E., Weitz, M., Savinkina, A., Schackman, B. R., Wang, J., Madushani, R. W. M. A., Morgan, J. R., Barocas, J. A., Walley, A. Y., et al. (2023) · JAMA Network Open

Opioid Use Disorder TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 21

Economic benefits of substance use disorder treatment: A systematic literature review of economic evaluation studies from 2003 to 2021

Fardone, E., Montoya, I. D., Schackman, B. R., & McCollister, K. E. (2023) · Journal of Substance Use and Addiction Treatment

Substance Abuse Treatment and OutcomesHealth Systems, Economic Evaluations, Quality of Life

Cited by 21

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 19